https://orcid.org/0000-0003-4110-1214
Author notes
Source of Support: Razelle Kurzrock is funded in part by 5U01CA180888–08 and 5UG1CA233198–05. David Hong acknowledges support from the Center for Clinical and Translational Sciences (UL1 TR003167) and from MD Anderson’s Cancer Center Support Grant (P30 CA016672).
Competing Interests
Conflict of Interest: Razelle Kurzrock has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, TopAlliance, and the National Cancer Institute; consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc. and IDbyDNA; serves on the board of CureMatch and CureMetrix; and is a co-founder of CureMatch. David Hong has received research (inst)/grant funding (inst) from AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astra-Zeneca, Bayer, Biomea, Bristol-Myers Squibb, Daiichi-Sankyo, Deciphera, EDDC, Eisai, Eli Lilly, Endeavor, Erasca, Exelixis, F. Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Incyte Inc, Inhibrix Inc, Jounce Therapeutics Inc, Kyowa Kirin, Merck, Mirati, Navier, NCI-CTEP, Novartis, Numab, Pfizer, Pyramid Bio, Revolution Medicine, SeaGen, STCube, Takeda, TCR2, Turning Point Therapeutics, and VM Oncology; travel, accommodations, or expenses from AACR, ASCO, CLCC, Bayer, Genmab, SITC, and Telperian; and consulting, speaker, or advisory role from 28Bio, AbbVie, Acuta, Adaptimmune, Alkermes, Alpha Insights, Amgen, Affini-T, Astellas, Aumbiosciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, COR2ed, Cowen, Ecor1, Erasca, Fate Therapeutics, F.Hoffmann-La Roche, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, InduPro, Janssen, Liberium, MedaCorp, Medscape, Numab, Oncologia Brasil, ORI Capital, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Projects in Knowledge, Quanta, RAIN, Ridgeline, SeaGen, Stanford, STCube, Takeda, Tavistock, Trieza Therapeutics, Turning Point Therapeutics, WebMD, YingLing Pharma, and Ziopharm. Other ownership interests for David Hong: Molecular Match (Advisor), OncoResponse (Founder, Advisor), Telperian (Founder, Advisor).
.png?versionId=19845)
